Seer, Inc. (SEER) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Seer, Inc. is a life sciences technology company focused on the Proteograph Product Suite, which utilizes proprietary engineered nanoparticle technology to enable deep proteomic analysis. The company is in the early stages of commercialization, operating with a history of net losses and negative cash flows from operations. It is classified as a smaller reporting company and non-accelerated filer.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $4.2 million | $3.1 million |
| Gross Profit | $2.1 million | $1.4 million |
| Gross Margin | 49% | 44% |
| Operating Loss | $(20.7) million | $(25.2) million |
| Net Loss | $(19.9) million | $(20.7) million |
| Cash & Investments | $285.3 million | N/A |
| Accumulated Deficit | $(412.3) million | N/A |
| Operating Cash Flow | $(11.4) million | $(10.5) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 37% year-over-year to $4.2 million, driven by a 73% increase in product revenue and a 195% increase in service revenue.
- Related Party Revenue Decline: Related party revenue dropped 95% to $0.05 million, compared to $0.95 million in Q1 2024, reflecting a shift away from concentration with a single related party customer.
- Expense Reduction: Total operating expenses decreased 14% to $22.8 million. Selling, general, and administrative (SG&A) expenses fell 20% primarily due to a $2.3 million reduction in stock-based compensation. R&D expenses decreased 7%.
- Investment Loss: The company recorded a $1.6 million loss on an equity method investment in PrognomiQ, Inc., a related party, which was not present in the prior year.
- Share Repurchases: The company repurchased 352,000 shares of Class A common stock for $0.7 million during the quarter.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes cash, cash equivalents, and investments of $285.3 million are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring significant operating losses in the near term.
- Commercialization Strategy: The company is focused on expanding the installed base of the Proteograph Product Suite and increasing utilization of consumables. It is building sales and marketing infrastructure in the U.S., Europe, and Asia-Pacific.
- Key Risks:
- Profitability: No assurance that the company will achieve or sustain profitability.
- Customer Concentration: While reduced, revenue remains concentrated; two customers accounted for 12% and 10% of revenue in Q1 2025.
- Supply Chain: Reliance on a single contract manufacturer (Hamilton Company) for the SP100 automation instrument.
- Intellectual Property: Ongoing challenges to patents, including Inter Partes Review petitions filed by competitors in late 2024.
- Regulatory: Risks associated with FDA regulation if products are deemed medical devices rather than research use only (RUO).
Investor Verification Checklist
- Verify the sustainability of the 37% revenue growth rate and the mix shift from related party to third-party customers.
- Monitor the burn rate relative to the $285.3 million cash position to assess runway beyond the 12-month management estimate.
- Review the status of the Inter Partes Review (IPR) challenges filed against the company's core patents in late 2024.
- Assess the impact of the $1.6 million loss on the PrognomiQ investment and the strategic value of that relationship.
- Confirm the progress of the share repurchase program and its impact on cash reserves.